Pembrolizumab adjuvant (resected NSCLC; KEYNOTE-671)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PEMBROLIZUMAB |
|---|
| ID | REG-PEMBRO-ADJUVANT-NSCLC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-EARLY-2024 SRC-KEYNOTE-671-WAKELEE-2023 SRC-NCCN-NSCLC-2025 |
Notes
KEYNOTE-671 adjuvant phase (Wakelee NEJM 2023): pembrolizumab 200 mg q3w × 13 cycles (~9 months) starting within 4-12 weeks of complete surgical resection, following 4 cycles of neoadjuvant pembrolizumab + cisplatin-based doublet (REG-PEMBRO-CHEMO-NEOADJ-NSCLC). Total perioperative pembrolizumab exposure: 17 cycles / ~1 year. EFS HR 0.58 and OS HR 0.72 reflect the contribution of the full perioperative package; adjuvant phase contribution is not independently dissectable from the trial design. Distinct from REG-PEMBRO-ADJUVANT-MELANOMA (18 cycles, KEYNOTE-054 protocol) — separate Regimen entity to capture the KEYNOTE-671-specific cycle count and NSCLC-specific monitoring (post-resection pneumonitis baseline elevated; lower irAE-discontinuation threshold). Excludes patients with EGFR-activating mutations or ALK fusion (FDA label) — driver-positive resectable NSCLC has superior adjuvant TKI options (osimertinib per ADAURA, alectinib per ALINA).
Used By
Indication
IND-NSCLC-PERIOPERATIVE-PEMBRO- IND-NSCLC-PERIOPERATIVE-PEMBRO
Regimen
REG-PEMBRO-CHEMO-NEOADJ-NSCLC- Pembrolizumab + cisplatin-based chemo (NSCLC neoadjuvant; KEYNOTE-671)